Trial · NCT05643794
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment | Placebo (PBO) | 6.30 | 95% Confidence Interval 5.59 to 7.01 | score on a scale | |
| Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment | RLZ 12 Weeks | 5.76 | 95% Confidence Interval 5.11 to 6.41 | score on a scale | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | Run-In-PBO | 44 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | TP1-RLZ | 22 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | TP1-PBO | 41 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | TP2-RLZ/RLZ | 18 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | TP2-PBO/RLZ | 19 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | TP2-PBO/PBO | 19 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | Run-Out and SFU-RLZ/RLZ | 10 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | Run-Out and SFU-PBO/RLZ | 12 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | Run-Out and SFU-PBO/PBO | 11 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | Run-In-PBO | 0 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | TP1-RLZ | 3 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | TP1-PBO | 1 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | TP2-RLZ/RLZ | 0 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | TP2-PBO/RLZ | 0 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | TP2-PBO/PBO | 1 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | Run-Out and SFU-RLZ/RLZ | 0 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | Run-Out and SFU-PBO/RLZ | 0 | Participants | ||
| Number of Participants With TEAEs Leading to Withdrawal of IMP | Run-Out and SFU-PBO/PBO | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05643794/results